Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma.
Publication Title
Blood
Document Type
Article
Publication Date
11-7-2019
Keywords
Antineoplastic Agents; Humans; Isoquinolines; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Purines
Abstract
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL) represent indolent malignancies characterized by multiple episodes of relapse. Therapy has centered on agents that largely target the B-cell receptor pathway. Duvelisib is a second-generation oral inhibitor of phosphoinositide-3 kinase, downstream of the B-cell receptor pathway, approved in the United States for relapsed CLL/SLL and FL. Duvelisib represents a highly active agent, and ongoing investigations, including fixed-duration drug combinations and alternative dosing schedules, are aimed at reducing immune-mediated toxicities.
Clinical Institute
Cancer
Specialty/Research Institute
Oncology
Specialty/Research Institute
Hematology
